Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of mirtazapine and citalopram for depression in breast cancer patients
IRCT20220406054440N1Phase 2Completed
- Sponsor
- Golestan University of Medical Sciences
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of mirtazapine and citalopram in major depressive disorder (MDD) (2 arms), sponsored by Golestan University of Medical Sciences. Primary endpoint: Improvement in depressive symptoms. Started Apr 2022; status: completed.
02
Drugs
mirtazapinecitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20220406054440N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220406054440N1.